In the news
Oversight needed for clinical translation of genome-based tests
Comment: The work behind this report arose from concerns following multiple problems experienced with personalised medicine tests (gene expression profiling to guide cancer treatment) developed from research at the university – retracted papers and cancelled clinical trials - attributed to a lack of sufficiently rigorous oversight. However, the findings are likely to be broadly useful in developing a more robust approach to evaluating (and hence comparing) tests, though this will be a significant task given the highly complex nature of the data many such tests use. The next question is, who will take this forward?